AZD1152 in patients with Advanced Solid Malignancies-Study 3

Study identifier:D1531C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a continuous 7-day Intravenous Infusion in Patients With Advanced Solid Malignancies

Medical condition

Solid tumours

Phase

Phase 1

Healthy volunteers

Study drug

AZD1152

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Aug 2006

Primary Completion Date: -

Study Completion Date: 01 Jul 2007

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1164&filename=CSR-D1531C00003.pdf
Download
CSR-D1531C00003.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clincial Study Information

800-236-9933

information.center@astrazeneca.com

Contact Backup

Outside US

001-866-992-9276

Investigators

Principal Investigator

David Kerr

University of Oxford